Bristol-Myers Squibb shares rose more than 5% in the premarket and are now at $62.31. The company previously assessed ADMILPARANT's phase III ALOFT-IPF trial to treat idiopathic pulmonary fibrosis in adults reached a major endpoint.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.